all report title image
  • Published On : Feb 2019
  • Code : CMI2515
  • Industry : Pharmaceutical
  • Pages : 157
  • Formats :

Ticagrelor Market Insights

Ticagrelor is used along with aspirin to prevent serious life-threatening problems associated with heart and blood vessels in people suffering with heart attack or severe chest pain. It is also used to prevent development of blood clots with coronary stents in patients having history of heart attack or severe chest pain. The global ticagrelor market is expected to grow at a significant growth rate during the forecast period, owing to high patient pool suffering from heart problems, increasing generic drug development, and improving market access scenarios.

The global ticagrelor market was valued at US$ 1,145.0 million in 2017, and is expected to witness a CAGR of 12.3% during the forecast period (2018 – 2026).

Figure 1. Global Ticagrelor Market Value (US$ Mn) Analysis and Forecast and Absolute $ Opportunity

Ticagrelor  | Coherent Market Insights

Source: Coherent Market Insights Analysis

Rising Global Burden of Heart Diseases is expected to Drive Growth of the Ticagrelor Market

Increasing burden of heart diseases has direct impact on global morbidity and mortality. For instance, according to American Heart Association and America Stroke Association report 2017 statistics update, cardiovascular disease is listed as the underlying cause of death, accounted for nearly 801,000 deaths in 2017, causing about 1 of every 3 deaths in the U.S. Same source also stated that about 92.1 million American adults were living with some form of cardiovascular disease or the after-effects of stroke in 2017.

Moreover, significant increase in the number of approvals from the U.S. Food and Drug Administration (USFDA) for ticagrelor will aid in the growth of ticagrelor market during the forecast period. For instance, in July 2018, USFDA permitted approval for ticagrelor tablets, manufactured by Alembic Pharmaceuticals, to reduce the rate of cardiovascular deaths and stroke in patients with acute coronary syndrome (ACS), or a history of myocardial infarction (MI).

Furthermore, instances of product failures will hamper growth of the ticagrelor market during the forecast period. For instance, in October 2016, drug Brilinta containing 90 mg ticagrelor manufactured by AstraZeneca plc failed to demonstrate its benefit over clopidogrel for a new indication in peripheral artery disease (PAD). This led to decreased shares of Brilinta by 1% in October 2016.

Ticagrelor Market- Regional Analysis

Regional segmentation of the global ticagrelor market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America holds the chief stake in the ticagrelor market, owing to increase in mergers and acquisitions of key players. For instance, in November 2017, PhaseBio Pharmaceuticals, Inc. entered into an exclusive, worldwide license agreement with MedImmune, the global biologics research and development arm of AstraZeneca, for PB2452 (formerly MEDI2452), a phase 1-ready reversal agent for ticagrelor. Ticagrelor binds reversibly with the receptors present on platelets.

Europe is also expected to observe significant growth in the global ticagrelor market, owing to increasing approvals for new ticagrelor formulation development in the region. For instance, in May 2017, the European Commission granted marketing authorization for AstraZeneca’s Brilique (ticagrelor) orodispersible tablets (ODT) as a new method of treatment administration. This tablet is effective for patients with difficulty in swallowing and in emergency cases.

Ticagrelor  | Coherent Market Insights

Source: Coherent Market Insights Analysis

Ticagrelor Market- Competitive Landscape

Key players operating in the ticagrelor market include C.H. Boehringer Sohn AG & Ko. KG, Pfizer Inc., Eli Lilly and Company, AstraZeneca plc, Natco Pharma Limited, Anhui Haikang Pharmaceutical Co., Ltd., Avra Laboratories Pvt. Ltd., and Sun Pharmaceutical Industries Ltd.

Ticagrelor, a drug commonly used as a platelet aggregation inhibitor, received approval from U.S. Food and Drug Administration (USFDA) in July 2011 and in the European Union by the European Commission in December, 2010. Ticagrelor is used for the prevention of thrombotic events such as stroke or heart attack in people with acute coronary syndrome or myocardial infarction with ST wave elevation.

Market Dynamics

Rising prevalence of cardiovascular diseases is attributed to rising geriatric population and changing lifestyles. According to World Health Organization (WHO), around 17.9 million people every year die due to cardiovascular diseases (CVDs), which is about 31% of all global deaths. This is expected to positively impact growth of the ticagrelor market over the next decade.

Furthermore, in September 2016, WHO launched the Global Hearts Initiative through which WHO is supporting governments around the world to improve efforts on CVD prevention and control. Thus, increasing number of non-government and government initiatives, in order to aid in prevention of CVD is expected to help in propelling growth of the ticagrelor market over the forecast period.

Key features of the study:

  • This report provides in-depth analysis of the ticagrelor market, market size (US$ Mn) and cumulative annual growth rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global ticagrelor market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include C.H. Boehringer Sohn AG & Ko. KG, Pfizer Inc., Eli Lilly and Company, AstraZeneca plc, Natco Pharma Limited, ANHUI HAIKANG PHARMACEUTICAL CO., LTD., Avra Laboratories Pvt Ltd., and Sun Pharmaceutical Industries Ltd
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global ticagrelor market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for ticagrelor market, research and consulting firms, new entrants, and financial analysts

 

Detailed Segmentation:

  • Global Ticagrelor Market, By Strength:
    • 60 mg
    • 90 mg
  • Global Ticagrelor Market, By Indication:
    • Acute Coronary Syndrome
    • Ischemic Stroke
  • Global Ticagrelor Market, By Distribution Channel:
    • Hospital pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Ticagrelor Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Strength:
        • 60 mg
        • 90 mg
      • By Indication:
        • Acute Coronary Syndrome
        • Ischemic Stroke
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Strength:
        • 60 mg
        • 90 mg
      • By Indication:
        • Acute Coronary Syndrome
        • Ischemic Stroke
      • By Distribution Channel:
        • Hospital pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Strength:
        • 60 mg
        • 90 mg
      • By Indication:
        • Acute Coronary Syndrome
        • Ischemic Stroke
      • By Distribution Channel:
        • Hospital pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Strength:
        • 60 mg
        • 90 mg
      • By Indication:
        • Acute Coronary Syndrome
        • Ischemic Stroke
      • By Distribution Channel:
        • Hospital pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Strength:
        • 60 mg
        • 90 mg
      • By Indication:
        • Acute Coronary Syndrome
        • Ischemic Stroke
      • By Distribution Channel:
        • Hospital pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Africa
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
      • By Strength:
        • 60 mg
        • 90 mg
      • By Indication:
        • Acute Coronary Syndrome
        • Ischemic Stroke
      • By Distribution Channel:
        • Hospital pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Company Profiles
    • C.H. Boehringer Sohn AG & Ko. KG *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Pfizer Inc.
    • Eli Lilly and Company
    • AstraZeneca plc
    • Natco Pharma Limited
    • ANHUI HAIKANG PHARMACEUTICAL CO., LTD.
    • Avra Laboratories Pvt. Ltd.
    • Sun Pharmaceutical Industries Ltd

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global ticagrelor market is estimated to surpass US$ 3.2 Billion by 2026.
Major players operating in the global ticagrelor market include C.H. Boehringer Sohn AG & Ko. KG, Pfizer Inc., Eli Lilly and Company, AstraZeneca plc, Natco Pharma Limited, Anhui Haikang Pharmaceutical Co., Ltd., Avra Laboratories Pvt. Ltd., and Sun Pharmaceutical Industries Ltd.
Instances of product failuresis one of the major factors that is expected to hamper growth of the market over the forecast period.
Rising global burden of heart diseasesis one of the major factors that is expected to propel growth of the market over the forecast period.
The global ticagrelor market is estimated to exhibit a CAGR of 12.3% over the forecast period (2018-2026).
Among regions, North America is expected to hold dominant position in the global ticagrelor market over the forecast period.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo